AVITA Medical Shares Jump 32.6% on RECELL Burn Treatment Data and Industry Events

Introduction

AVITA Medical Inc (NASDAQ: RCEL) is a Santa Clarita, California-based regenerative medicine company specializing in acute wound care solutions. Its flagship RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, utilizes a patient’s own skin cells to facilitate healing at the point of care. The company also holds exclusive U.S. rights to market PermeaDerm® (a biosynthetic wound matrix) and Cohealyx™ (a collagen-based dermal matrix).

Corporate Structure

• Headquarters: Santa Clarita, California
• Founded: 2008
• Employees: 201–500 (LinkedIn)
• Key Leadership:
– Jim Corbett, Chief Executive Officer
– Robert McNamara, Chief Financial Officer
• Public Listings:
– NASDAQ under ticker RCEL
– Australian Securities Exchange under ticker AVH

Wound care by Diana Polekhina

Recent Developments and News

On August 8, 2025, AVITA filed a Form S-8 registering securities for its Amended and Restated 2020 Omnibus Incentive Plan, indicating a focus on employee equity awards. On August 12 and August 18, 2025, the company submitted Form 8-K reports: the former addressing press releases and exhibits, and the latter concerning material agreements.

At the 2025 European Burns Association Congress, data indicated that RECELL treatment reduced hospital stays by 36% in adult patients with deep partial-thickness burns affecting up to 30% total body surface area. AVITA participated in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. From September 10–13, 2025, the company exhibited at the 84th Annual Meeting of the American Association for the Surgery of Trauma and Clinical Congress of Acute Care Surgery in Boston. During this period, AVITA also participated in the American Burn Association’s Surgeon Forum in Chicago on September 11–12.

Financial and Strategic Analysis

As of September 15, 2025, AVITA Medical shares closed at $6.05, with a gain of 32.63% on 3,156,675 shares traded. This increase may be attributed to the company's clinical data and participation in industry events. AVITA’s strategic priorities include expanding indications for the RECELL platform (including repigmentation of vitiligo lesions), advancing research and development into chronic-wound and aesthetic applications, and utilizing partnerships—historically including BARDA funding—to support U.S. commercialization. The August 8 S-8 filing reflects a commitment to aligning employee incentives with long-term performance goals.

Market Position and Industry Context

The global acute wound care market is influenced by the demand for therapies that reduce donor-skin requirements, shorten hospital stays, and lower overall treatment costs. AVITA’s RECELL System competes with conventional autografting by using autologous skin suspensions to facilitate the regeneration of the epidermis, deposition of extracellular matrix proteins, and restoration of pigmentation. The company’s exclusive distribution rights for PermeaDerm and Cohealyx further enhance its product portfolio. Ongoing FDA approvals and the release of real-world data are integral to maintaining market access and supporting reimbursement efforts.

tl;dr

AVITA Medical’s stock increased by 32.63% on September 15, 2025, following clinical data presented at the 2025 European Burns Association Congress and participation in prominent industry events in Boston and Chicago. With the FDA-approved RECELL GO in use and upcoming presentations at key burn-care forums, the company aims to secure additional indications, publish longer-term cost-effectiveness results, and translate pipeline advancements into market uptake.